Puma Biotechnology Inc
NASDAQ:PBYI

Watchlist Manager
Puma Biotechnology Inc Logo
Puma Biotechnology Inc
NASDAQ:PBYI
Watchlist
Price: 2.81 USD 2.18% Market Closed
Market Cap: 137.9m USD
Have any thoughts about
Puma Biotechnology Inc?
Write Note

Puma Biotechnology Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Puma Biotechnology Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Puma Biotechnology Inc
NASDAQ:PBYI
Stock-Based Compensation
$8.9m
CAGR 3-Years
-38%
CAGR 5-Years
-33%
CAGR 10-Years
-10%
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Puma Biotechnology Inc
Glance View

Market Cap
137.9m USD
Industry
Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 196 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

PBYI Intrinsic Value
4.48 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Puma Biotechnology Inc's Stock-Based Compensation?
Stock-Based Compensation
8.9m USD

Based on the financial report for Sep 30, 2024, Puma Biotechnology Inc's Stock-Based Compensation amounts to 8.9m USD.

What is Puma Biotechnology Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
-10%

Over the last year, the Stock-Based Compensation growth was -14%. The average annual Stock-Based Compensation growth rates for Puma Biotechnology Inc have been -38% over the past three years , -33% over the past five years , and -10% over the past ten years .

Back to Top